We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Osi Pharmaceuticals Inc. (MM) | NASDAQ:OSIP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 57.49 | 0 | 01:00:00 |
From May 2019 to May 2024
Astellas Pharma Inc. (4503.TO) said Thursday it received enough offers of shares in U.S. cancer drug developer OSI Pharmaceuticals Inc. (OSIP) to complete its takeover of the company, a deal that could be worth up to $4.0 billion.
The Tokyo-based drug maker said the number of OSI shares offered by shareholders during the tender period through Wednesday was equivalent to 87% of the company's outstanding stocks, including those to be offered within three business days under the process known as guaranteed delivery.
The tender offer, which started as a hostile takeover attempt in early March, has been repeatedly extended as OSI sought bids higher than Astellas' initial offer of $52 a share.
Astellas and OSI agreed on the acquisition after the Japanese company raised the offer to $57.50 on May 17. OSI shares ended at $57.42 Wednesday on the Nasdaq Stock Market.
-By Kazuhiro Shimamura, Dow Jones Newswires; 813-6269-2790; kazuhiro.shimamura@dowjones.com
1 Year Osi Pharmaceuticals Chart |
1 Month Osi Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
